 Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat RefractoryRelapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat RefractoryRelapsed Lymphoma and Chronic Lymphocytic Leukemia Patients 